Double hit lymphoma: the <scp>MD A</scp> nderson <scp>C</scp> ancer <scp>C</scp> enter clinical experience
Yasuhiro Oki(Unknown), Jason R. Westin(The University of Texas MD Anderson Cancer Center), Maria Alma Rodriguez(The University of Texas MD Anderson Cancer Center), Hun Ju Lee(The University of Texas MD Anderson Cancer Center), Luis Fayad(The University of Texas MD Anderson Cancer Center), Yago Nieto(The University of Texas MD Anderson Cancer Center), Issa F. Khouri(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Nathan Fowler(Repligen (United States)), R. Eric Davis(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Felipe Samaniego(The University of Texas MD Anderson Cancer Center), Larry W. Kwak(The University of Texas MD Anderson Cancer Center), Michelle A. Fanale(Pfizer (United States)), Jorge Romaguera(The University of Texas MD Anderson Cancer Center), Michael Wang(St. Joseph Health System), Pei Lin(The University of Texas MD Anderson Cancer Center), Mohamed Ahmed(The University of Texas MD Anderson Cancer Center), Long Ma(The University of Texas MD Anderson Cancer Center), Francesco Turturro(The University of Texas MD Anderson Cancer Center), Leonard Jeffrey Medeiros(The University of Texas MD Anderson Cancer Center), Bouthaina S. Dabaja(The University of Texas MD Anderson Cancer Center), Fredrick B. Hagemeister(The University of Texas MD Anderson Cancer Center), Mansoor Noorani(The University of Texas MD Anderson Cancer Center), Chelsea C. Pinnix(The University of Texas MD Anderson Cancer Center)
Cited by 364
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies
|Journal of Clinical Oncology|2012|1.1k
Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
|Nature Medicine|2015|1.1k